What is Xolair?
Xolair (omalizumab) is a prescription medication used to treat chronic idiopathic urticaria (CIU) in adults and adolescents aged 12 and older whose hives were not controlled by antihistamine treatment [1]. It is also indicated for severe or very severe persistent asthma in adults and adolescents aged 12 and older with an allergic component whose symptoms are inadequately controlled with inhaled corticosteroids [2]. Xolair works by binding to immunoglobulin E (IgE) in the body, thereby reducing the amount of IgE that can trigger allergic reactions [3].
How does Xolair work for asthma?
For asthma patients with an allergic component, Xolair targets immunoglobulin E (IgE), a key driver of allergic inflammation. By binding to IgE in the bloodstream, Xolair prevents it from attaching to mast cells and basophils. This reduces the release of histamine and other inflammatory mediators that cause asthma symptoms such as wheezing, shortness of breath, and chest tightness [2]. It is administered as an injection [3].
What are the uses of Xolara?
Xolara has two primary indications:
* Chronic Idiopathic Urticaria (CIU): It is used for adults and adolescents aged 12 and older when antihistamines have not adequately controlled their hives [1].
* Severe or Very Severe Persistent Asthma: It is used for adults and adolescents aged 12 and older who have an allergic component to their asthma and whose symptoms are not managed well with inhaled corticosteroids [2].
How is Xolara administered?
Xolara is administered as a subcutaneous injection, meaning it is injected under the skin [3]. The dosage and frequency of administration depend on the patient's weight and IgE levels [2][1].
What are the potential side effects of Xolara?
Common side effects associated with Xolara include injection site reactions (redness, swelling, itching, pain), headache, fatigue, dizziness, joint pain, and increased appetite [3]. A rare but serious side effect is anaphylaxis, a severe allergic reaction that can occur immediately or days after injection [3]. Patients should be monitored for signs of anaphylaxis, such as difficulty breathing, swelling of the face or throat, rash, itching, or fainting [3].
How does Xolara compare to other asthma treatments?
Xolara is a biologic therapy used as an add-on treatment for severe allergic asthma when other medications, like inhaled corticosteroids, have not sufficiently controlled symptoms [2]. Unlike bronchodilators that offer quick relief or inhaled corticosteroids that reduce airway inflammation, Xolara targets the underlying allergic mechanisms by reducing IgE levels [2]. Its use is generally reserved for patients with a specific allergic component to their asthma and elevated IgE levels [2].
When does Xolara's patent protection end?
Information regarding specific patent expiry dates for Xolara is typically tracked by specialized services. DrugPatentWatch.com is a resource that monitors drug patents and exclusivity [4].
Who manufactures Xolara?
Xolara is developed and marketed by Novartis [5].